News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly Statins versus PCSK9 inhibitors: new metabolomic analysis New meta-analysis of PCSK9 inhibitors: a mortality benefit or not?Coronary artery calcium in familial hypercholesterolaemia Stratifying risk in familial hypercholesterolaemia: does coronary artery calcium have a role?ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

News

Two more analyses show efficacy of alirocumab in diabetes

Two recent analyses add to the body of evidence supporting the efficacy and tolerability of the PCSK9 inhibitor alirocumab in patients with type 2 diabetes mellitus (T2DM), including those with mixed dyslipidaemia. The first report (1) was a pooled analysis of 5 placebo-controlled Phase 3…

Posted on 17 August 2018 | Posted in News

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. The PCSK9 Education and Research Forum is focused on raising awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target. As part of its remit, PCSK9 Education and Research Forum offers healthcare professionals open access to electronic and multimedia platforms providing real-time reporting of significant developments and news; authoritative analysis and commentary; as well as an extensive library of accredited educational materials tailored to the differing needs of registrants.

Our Partnership and Outreach

Through its unique global network of researchers and clinicians, the PCSK9 Education and Research Forum connects academic institutions, research organisations and societies which share the Forum’s commitment to the reduction of CVD mortality and morbidity through improved management of atherosclerotic dyslipidaemia. The Forum builds on educational partnerships with such organisations through jointly sponsored symposia, as well as accredited research and educational programmes.

Educational Partners and Supporters

News

Two more analyses show efficacy of alirocumab in diabetes

Find out more

About PCSK9 Education and Research Forum

Our Partnership and Outreach